University of Dundee

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Masaryk Memorial Cancer Institute

Centre National De La Recherche Scientifique

Université Paul Sabatier (toulouse Iii)

Université Claude Bernard Lyon I

Hospices Civils De Lyon

Institut Claudius Regaud

Université Montpellier 2 Sciences Et Techniques

Vojtesek, Borivoj

Jean-Christophe Bourdon

Curtis C Harris

Pierre Roux

David Philip Lane

Borivoj Vojtesek

Izumi Horikawa

Kaori Fujita

Olivier Terrier

Manuel Rosa-Calatrava

Christophe Cazaux

Jean-Sébastien Hoffmann

Alice Machado Da Silva

Henri Roche

David P Lane

Stéphanie Vinot

Gilles Gadea

Kenneth Fernandes

Stephanie Vinot

Christelle Anguille

Manuel Rosa-calatrava

The present invention provides methods and compositions for modulating cell senescence and cell proliferation using isoforms of the p53 tumor suppressor protein. The methods and compositions of the invention find use in inhibiting cancer cell growth or in generating populations of cells for tissue regeneration through the modulation of cell senescence and proliferation.

Therapeutic applications of p53 isoforms in regenerative medicine, aging and cancer

The present invention relates to a method for improving the production of an influenza virus, and in particular influenza vaccine seeds, or a vaccine directed against an influenza virus, characterized in that the production is carried out in the presence of an inhibitor of the interaction between the Mdm2 protein and the p53 protein.

Method for improving the production of influenza viruses and vaccine seeds

Therapeutic applications of P53 isoforms in regenerative medicine, aging and cancer

The present invention relates to a method for diagnosing aggressiveness and/or genetic instability of a cancer in a patient from a cancer sample of the patient. The method includes measuring in vitro the expression level of the POLQ gene and the expression level of a control gene in the patient cancer sample, calculating an expression level ratio of the expression level of POLQ to the expression of the control gene in the patient cancer sample, comparing the expression level ratio to a corresponding threshold value, and diagnosing cancer aggressiveness and genetic instability if the POLQ expression level ratio is superior to a corresponding threshold value. Dedicated microarrays and kits are also described, as well as a method of selecting a suitable treatment.

Signature for the diagnosis of cancer aggressiveness and genetic instability

Growing community of inventors

Dundee, United Kingdom

Jean-Christophe Bourdon